Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

Satellos Bioscience's experimental small-molecule drug for Duchenne muscular dystrophy is showing positive results as a stand-alone treatment, but Phil Lambert, Ph.D., the company's chief scientific ...

Repurposing existing therapies may help slow muscle weakness in patients with Duchenne muscular dystrophy, a new study ...

Phil Lambert, Ph.D., chief scientific officer of Satellos Bioscience Inc., explains the mechanism of action of the company's experimental Duchenne muscular dystrophy drug, SAT-3247, and the thinking ...

The findings of a new study lend support for type 1 diabetes autoantibody screening in people with other autoimmune ...

Tracking the trajectory of symptoms may be an improvement over the traditional way of collecting patient-reported outcomes ...

Approximately 57% of Americans are lonely, with younger generations, Gen Z and Millennials, reporting higher levels than ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The risk of major cardiac events was 50% higher in adult-onset type 1 diabetes than in population controls, and the risk of ...

Gut bacteria produce metabolites that influence drug metabolism and affect immune cell function, potentially enhancing or ...

Despite high specificity, the tests show low sensitivity for early-stage cancers, necessitating further validation through ...

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the ...